I'd also be interested in this!
I just mean this could have been two posts - one about the paper and one about the experience of publishing the paper. Both would be very valuable.
I think it is disappointing that so many comments are focusing on arguing with the paper rather than discussing the challenges outlined in the post. From a very quick reading I don't find any of the comments here unreasonable but I do find them to be talking about a different topic. It would be better if we could separate out the discussion of "red teaming" EA from the discussion of this particular paper
Good post Sanjay, though I think a better title would be "Why SoGive is not yet updating charity ratings after malaria vaccine news" though. I don't disagree with any of the points you've made - and there are certainly large uncertainties around this, but there is at least a significant possibility that when some uncertainties are resolved this could displace nets in terms of cost-effectiveness. So its certainly a very promising development and even if we don't change our immediate funding priorities, we need to think about how they might change in the future.
I think this is potentially very significant news - i’m hoping to write a more detailed post once I’ve looked into it more but a previous 35% effective vaccine was found to be only marginally less cost effective than LLIN nets in preventing malaria spread - a 75% effective (and cheap!) vaccine has at least the potential to shoot to the top of our list of most effective global health and poverty interventions, to the extent that we may want to think about pooling EA funds towards the project (perhaps creating a special EA malaria vaccination fund)
US citizenship is extremely valuable and your career opportunities at this stage are likely to be far more valuable to you in future earnings expectations than a few additional percentage points on investments. In terms of investing, my understanding is that you are best off investing in the US and that there are US investment options open to you (Charles Schwab I believe often comes up as a broker in this area) rather than in the UK.
Finally the mystery of how CEEALAR got named is solved :D
Minor typo - The DOI for Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development. Clinical Infectious Diseases has a trailing e in the url which causes the link to fail
I’ve vaguely thought about this but I’m not a significant enough donor that I’m going to register in people’s calculations, and if I’m donating primarily through third party funds then I’m already quite disconnected. (I.e my money isn't arriving at the charity in December/Feb in any case). I think I prefer the "end of the year" feeling and communal discussions like this to improve my donation habits.
I attended the "Other Place" but my serious answer is the same for Oxford. Research online which colleges are richest (and most prestigious) and apply there unless you have a strong reason to prefer another college. The richest colleges have more grants, funding and opportunities available to students - you can save thousands of pounds and get access to opportunities just not available elsewhere. (For example I found out early on that my peers at another Cambridge college received a grant for books 3x larger each term than my college did - which in turn was more than another gave all year) - likely the additional additive networking opportunities are equally as valuable. Connections to well known EA's within faculty are probably overrated, unless you can be sure of a close connection to a faculty member for several years (as what Cambridge would call a Director of Studies) you won’t gain a significant advantage and you can pursue the interests outside of your formal study program.